Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Nvidia stock rises after the artificial-intelligence chip maker unveils its next generation gaming graphic cards, while ...
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
Mashpee Wampanoag educator Kitty Hendricks-Miller (Nanaweetah), consults on PBS 'Molly of Denali' as Cape-based tribe debuts ...
Fort Smith area plaintiffs have not shown they suffered physical harm from an intermittent but widespread offensive smell in ...
The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.
Investor's Business Daily on MSN1h
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a ...
Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...
Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.
The state of Alaska and Alaskans themselves have always had a clear record that they prefer to call North America’s tallest ...
Denali Bancorporation, Inc., the parent company of Denali State Bank, announced a $0.05 increase in its quarterly cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback